Promethazine by itself is not a controlled substance under federal law. The DEA assigns it no schedule, meaning it sits in the same regulatory category as other prescription medications like antibiotics or blood pressure drugs. However, promethazine combined with codeine in cough syrup is a Schedule V controlled substance, the lowest level of federal scheduling. This distinction matters because the two products carry very different legal and safety profiles.
Why Promethazine Isn’t Scheduled
Promethazine is an antihistamine, part of a class of older allergy medications. It works primarily by blocking histamine receptors, which is why it treats allergic reactions, and it also affects several other receptor systems in the brain that produce its strong sedating effects. Unlike opioids or benzodiazepines, it doesn’t directly activate the brain’s reward pathways in a way that produces a classic “high” on its own. That’s the main reason the DEA doesn’t place it on a controlled substance schedule.
That said, promethazine still requires a prescription in all 50 states. It carries the “Rx only” designation, classifying it as a “dangerous drug” under pharmacy law, meaning you cannot buy it over the counter. A pharmacist cannot legally dispense it without a valid prescription from a licensed provider.
The Codeine Combination Is Different
When promethazine is mixed with codeine in a cough syrup, the product becomes a Schedule V controlled substance. Codeine is an opioid, and its presence triggers the scheduling requirement. Schedule V is the least restrictive controlled substance category, but pharmacies must still track dispensing, and refill limits apply.
This combination syrup became widely known in the late 1990s when reports emerged from Texas of teenagers drinking it recreationally. One study found that 25% of at-risk youth reported using codeine-promethazine cough syrup to get high at least once. The practice spread through hip-hop culture under names like “lean,” “purple drank,” and “sizzurp,” and it remains a significant public health concern.
Misuse Potential Despite No Schedule
The fact that plain promethazine isn’t a controlled substance doesn’t mean it’s free of misuse concerns. Promethazine is thought to intensify the effects of opioids, and a substantial underground market exists for it. A study of chronic pain patients found that 9% tested positive for promethazine in urine samples, and half of those people had no active prescription for it. That’s a strong signal of nonmedical use.
People who use heroin, those in methadone maintenance programs, and teenagers have all been identified as populations where promethazine misuse is common. Some patients obtain prescriptions by reporting fake symptoms like nausea or allergies, then use the drug alongside opioids. Researchers have recommended that promethazine be considered a potential drug of abuse, particularly in populations already using opioids.
No state has independently added plain promethazine to its controlled substance schedules. New York’s controlled substance law, for example, does not list it. But some providers and pharmacies treat it with extra caution, especially in areas where “lean” culture is prevalent.
What Promethazine Is Prescribed For
Promethazine has a wide range of FDA-approved uses. It treats seasonal and year-round allergies, allergic skin reactions like hives, and allergic conjunctivitis. It’s also approved for preventing and controlling nausea and vomiting, particularly around surgery and anesthesia. Motion sickness prevention is another common use. Hospitals frequently use it for sedation before and after surgery, and it’s sometimes given alongside pain medications to enhance their effects in a clinical setting.
Side Effects and Safety Warnings
Drowsiness is the most common side effect, and it can be significant. Dry mouth, dizziness, blurred vision, and loss of coordination are also frequent. Some people experience restlessness, nightmares, or difficulty sleeping, which can seem counterintuitive for a sedating drug.
The more serious concern is respiratory depression, particularly in children. Promethazine carries an FDA boxed warning, the most serious type, stating that it should never be used in children under age 2 because of the risk of fatal slowing or stopping of breathing. Postmarketing reports documented deaths in young children after receiving the drug. For children aged 2 and older, the FDA recommends caution and warns against combining promethazine with other medications that slow breathing.
Rare but serious reactions include fever with stiff muscles and decreased alertness (a condition related to the drug’s effects on brain signaling), seizures, uncontrollable muscle movements, hallucinations, and irregular heartbeat. Yellowing of the skin or eyes, which signals liver problems, also requires immediate medical attention.
How It’s Regulated in Practice
Because plain promethazine is prescription-only but not scheduled, pharmacists dispense it like any other non-controlled prescription medication. There are no special ID requirements, no limits on refills beyond what the prescriber writes, and no requirement to report dispensing to a state prescription drug monitoring program. The codeine combination, by contrast, gets logged in monitoring databases and follows controlled substance dispensing rules.
This regulatory gap is part of why misuse persists. Without monitoring program tracking, it’s easier for someone to obtain promethazine prescriptions from multiple providers without detection. Some pharmacists and clinics have adopted informal policies of flagging frequent promethazine requests, but no federal or state law mandates this.